CAJ | 학술논문

卵巢癌是女性生殖道恶性肿瘤致死率最高的肿瘤，尽管其发病率低于子宫颈癌及子宫内膜癌，但死亡率却位居首位。肿瘤细胞减灭术联合术后以铂类药物为主的化疗是目前卵巢癌的标准治疗方案。对晚期卵巢癌而言，满意的初次肿瘤细胞减灭术是非常重要而且必要的，但同时也存在诸多困难和挑战，常难以达到满意肿瘤减灭效果及合并严重手术并发症。为了增加晚期卵巢癌满意的初次肿瘤细胞减灭术的比率、减少手术并发症，近年来国内外采用术前新辅助化疗（NACT ），借以改善晚期卵巢癌手术条件，提高满意肿瘤细胞减灭率。针对晚期卵巢癌的 NACT 目前尚存在许多争议，对于患者术后后续化疗的耐药性及5年存活率的改善等问题一直悬而未决。本文就晚期卵巢癌术前 NACT 可行性问题作一讨论。
란소암시녀성생식도악성종류치사솔최고적종류，진관기발병솔저우자궁경암급자궁내막암，단사망솔각위거수위。종류세포감멸술연합술후이박류약물위주적화료시목전란소암적표준치료방안。대만기란소암이언，만의적초차종류세포감멸술시비상중요이차필요적，단동시야존재제다곤난화도전，상난이체도만의종류감멸효과급합병엄중수술병발증。위료증가만기란소암만의적초차종류세포감멸술적비솔、감소수술병발증，근년래국내외채용술전신보조화료（NACT ），차이개선만기란소암수술조건，제고만의종류세포감멸솔。침대만기란소암적 NACT 목전상존재허다쟁의，대우환자술후후속화료적내약성급5년존활솔적개선등문제일직현이미결。본문취만기란소암술전 NACT 가행성문제작일토론。
Ovarian cancer has the highest death rate in female genital tract tumors .Although its incidence is lower than that of cervical cancer and endometrial cancer ,the mortality rate is the highest .The present standard treatment plan for ovarian cancer is tumor cytoreductive surgery combined with postoperative platinum-based chemotherapy .In late stage ovarian cancer ,the optimal debulking is necessary .However ,debulking has its difficulties and challenges because there is a high probability of residual tumor and surgical complications .In order to increase the probability of optimal debulking and to reduce preoperative complications , the process of first neoadjuvant chemotherapy (NACT ) should be followed by debulking surgery ,and then chemotherapy again is introduced as a substitute process for primary surgery .Currently there is still a lot of debate regarding neoadjuvant chemotherapy for advanced ovarian cancer .NACT may improve conditions for advanced ovarian cancer surgery and increase the rate of cytoreductive .On the other hand ,NACT may increase drug resistance in postoperative follow-up chemotherapy and 5-year survival rate of patients treated with NACT is not significantly different from rate of patients with standard treatment . This article aims to discuss the feasibility of preoperative neoadjuvant chemotherapy in advanced ovarian carcinoma .